Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

NCT02252107 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT02252107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02252107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
Lead sponsor
Radboud University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
May 31, 2019
Enrollment
46 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)